Purpose The Prostate Cancer Prevention Trial demonstrated a 25% reduction in period
prevalence of prostate cancer in men randomly assigned to 5 mg/d of finasteride. However …

“Psa was a very strong predictor of subsequent prostate cancer,” says vickers,“such that it
can be used to risk-stratify patients.” in fact, the addition of other prognostic information …

(PCPT) have confirmed that, although finasteride is associated with increased detection of
high-grade disease, there is no concomitant effect on overall survival. It is hoped that this …

Purpose To assess the estimated effect of finasteride prevention of prostate cancer on
overall survival. Methods Data for our decision tree model came from men in the two arms …

“Psa was a very strong predictor of subsequent prostate cancer,” says vickers,“such that it
can be used to risk-stratify patients.” in fact, the addition of other prognostic information …

Abstract The Prostate Cancer Prevention Trial (PCPT) reported conclusively that finasteride
prevents or delays the detection of prostate cancer. One perplexing finding was that more …

Prostate cancer is the most common malignancy diagnosed and the second most common
cause of cancer death in American men. Although effective treatment strategies exist, the …

All forms of androgen-deprivation therapy, including finasteride, induce distinctive histologic
changes in benign and neoplastic prostatic epithelial cells, including cytoplasmic clearing …

The Prostate Cancer Prevention Trial, a randomized placebo-controlled study involving
nearly 19,000 men at 221 sites over 10 years, has shown that men who took the drug …

Editorial Comments: The original report from the PCPT (Prostate Cancer Prevention Trial)
demonstrated a 24% relative reduction in the diagnosis of prostate cancer among men with …